Treatment outcomes following continuous miglustat therapy in

Por um escritor misterioso

Descrição

Background Niemann-Pick disease Type C (NP-C) is a rare, progressive neurodegenerative disorder characterized by progressive neurodegeneration and premature death. We report data at closure of the NPC Registry that describes the natural history, disease course and treatment experience of NP-C patients in a real-world setting. Methods The NPC Registry was a prospective observational cohort study that ran between September 2009 and October 2017. Patients with a confirmed diagnosis of NP-C were enrolled regardless of treatment status. All patients underwent clinical assessments and medical care as determined by their physicians; data were collected through a secure internet-based portal. Results At closure on October 19, 2017, 472 patients from 22 countries were enrolled in the NPC Registry. Mean (standard deviation) age at enrollment was 21.2 (15.0) years, and 51.9% of patients were male. First neurological symptom onset occurred during the early-infantile (< 2 years), late-infantile (2 to < 6 years), juvenile (6 to < 15 years), or adolescent/adult (≥ 15 years) periods in 13.5, 25.6, 31.8, and 29.1% of cases, respectively. The most frequent neurological manifestations prior to enrollment included ataxia (67.9%), vertical supranuclear gaze palsy (67.4%), dysarthria (64.7%), cognitive impairment (62.7%), dysphagia (49.1%), and dystonia (40.2%). During infancy, splenomegaly and hepatomegaly were frequent (n = 199/398 [50%] and n = 147/397 [37.0%], respectively) and persisted in most affected patients. Of the 472 enrolled patients, 241 were continuously treated with miglustat during the NPC Registry observation period, of whom 172 of these 241 patients were treated continuously for ≥12 months. A composite disability score that assesses impairment of ambulation, manipulation, language, and swallowing was highest in the early-infantile population and lowest in the adolescent/adult population. Among the continuous miglustat therapy population, 70.5% of patients had improved or had stable disease (at least 3 of the 4 domains having a decreased or unchanged score between enrollment and last follow-up). The NPC Registry did not identify any new safety signals associated with miglustat therapy. Conclusions The profiles of clinical manifestations in the final NPC Registry dataset agreed with previous clinical descriptions. Miglustat therapy was associated with a stabilization of neurological manifestations in most patients. The safety and tolerability of miglustat therapy was consistent with previous reports.
Treatment outcomes following continuous miglustat therapy in
IJMS, Free Full-Text
Treatment outcomes following continuous miglustat therapy in
Large variation in effects during 10 years of enzyme therapy in
Treatment outcomes following continuous miglustat therapy in
Long-term safety and efficacy of cipaglucosidase alfa plus
Treatment outcomes following continuous miglustat therapy in
Update of treatment for mucopolysaccharidosis type III (sanfilippo
Treatment outcomes following continuous miglustat therapy in
Proportions of patients who received continuous miglustat therapy
Treatment outcomes following continuous miglustat therapy in
Effects of miglustat therapy on neurological disorder and survival
Treatment outcomes following continuous miglustat therapy in
Miglustat in late-onset Tay-Sachs disease: a 12-month, randomized
Treatment outcomes following continuous miglustat therapy in
Effects of miglustat therapy on neurological disorder and survival
Treatment outcomes following continuous miglustat therapy in
Miglustat: Package Insert
Treatment outcomes following continuous miglustat therapy in
History of NP-C manifestations for all patients in the NPC
Treatment outcomes following continuous miglustat therapy in
Increasing Enzyme Mannose-6-Phosphate Levels but Not Miglustat
de por adulto (o preço varia de acordo com o tamanho do grupo)